Business
Biophytis S A : enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Biophytis S A : enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in
About this update from Biophytis Sa
28 Jan 2026 07:30 CET Subscribe Issuer BIOPHYTIS See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo 16165_1385091_Press_Release__JointVenture.pdf Source Biophytis Provider Les Echos Company Name BIOPHYTIS ISIN FR001400OLP5 Symbol ALBPS Market Euronext Growth